Balyasny Asset Management
ELTX icon

Balyasny Asset Management’s Elicio Therapeutics ELTX Stock Holding History

Balyasny Asset Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-244,814
Closed -$2.62M – 3130
2026
Q1 		$2.62M Buy
244,814
+106,052
+76% +$1.02M ﹤0.01% 1669
2025
Q4 		$1.1M Sell
138,762
-9,314
-6% -$84.5K ﹤0.01% 2148
2025
Q3 		$1.62M Buy
+148,076
New +$1.5M ﹤0.01% 1903

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Balyasny Asset Management's ELTX Position: Q2 2026 in Review

Balyasny Asset Management sold out of Elicio Therapeutics (ELTX) in Q2 2026, closing a stake of 244,814 shares — an estimated $2.62M sold.

Balyasny Asset Management first reported a position in ELTX in Q3 2025 and held it in 3 quarters. The position peaked at $2.62M in Q1 2026. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Balyasny Asset Management reported no remaining Elicio Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 244,814 Elicio Therapeutics shares in Q2 2026, an estimated $2.62M.
  • Balyasny Asset Management first reported a position in Elicio Therapeutics in Q3 2025 and held it in 3 quarters.
  • Balyasny Asset Management's Elicio Therapeutics position peaked at $2.62M in Q1 2026.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.